Latest advances and current challenges in the treatment of multiple myeloma (Q37986287)

26 August 2017

title

Latest advances and current challenges in the treatment of multiple myeloma (English)

1 reference

26 August 2017

6

Kenneth Anderson

1 reference

26 August 2017

5

Paul G Richardson

1 reference

26 August 2017

4

Nikhil Munshi

1 reference

26 August 2017

2

Jacob Laubach

1 reference

26 August 2017

3

Noopur Raje

1 reference

26 August 2017

1

Anuj Mahindra

1 reference

26 August 2017

language of work or name

English

0 references

publication date

21 February 2012

1 reference

Nature Reviews Clinical Oncology

26 August 2017

published in

1 reference

26 August 2017

volume

9

1 reference

26 August 2017

issue

3

1 reference

26 August 2017

page(s)

135-143

1 reference

Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.15

21 January 2018

Cancer statistics, 2010

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.15

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.15

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.15

Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.15

Reiterative survival analyses of total therapy 2 for multiple myeloma elucidate follow-up time dependency of prognostic variables and treatment arms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.15

Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.15

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.15

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.15

Improved survival in multiple myeloma and the impact of novel therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.15

Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.15

Multiple myeloma: biology of the disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.15

Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.15

Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.15

Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.15

International staging system for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.15

Relationship of patient survival and chromosome anomalies detected in metaphase and/or interphase cells at diagnosis of myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.15

Prognostic and therapeutic significance of myeloma genetics and gene expression profiling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.15

Translocation t(14;16) and multiple myeloma: is it really an independent prognostic factor?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.15

Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.15

Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.15

Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.15

A phase 2 study of bortezomib in relapsed, refractory myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.15

Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.15

Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.15

Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.15

Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.15

Diagnostic evaluation of t(4;14) in multiple myeloma and evidence for clonal evolution.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.15

Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.15

Polymorphisms in the multiple drug resistance protein 1 and in P-glycoprotein 1 are associated with time to event outcomes in patients with advanced multiple myeloma treated with bortezomib and pegylated liposomal doxorubicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.15

Genomic screening for genes silenced by DNA methylation revealed an association between RASD1 inactivation and dexamethasone resistance in multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.15

Efficacy and safety of once-weekly bortezomib in multiple myeloma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.15

Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.15

Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.15

Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.15

A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.15

Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.15

In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.15

Combination of novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.15

PR-924, a selective inhibitor of the immunoproteasome subunit LMP-7, blocks multiple myeloma cell growth both in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.15

Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.15

Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.15

Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.15

Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.15

AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3beta activation and RNA polymerase II inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.15

Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.15

Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.15

p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.15

Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.15

Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.15

Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.15

Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.15

First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.15

Neutralizing B-cell activating factor antibody improves survival and inhibits osteoclastogenesis in a severe combined immunodeficient human multiple myeloma model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.15

Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.15

Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.15

Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.15

Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.15

The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.15

Infusion of haplo-identical killer immunoglobulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.15

Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.15

Identification of novel antigens with induced immune response in monoclonal gammopathy of undetermined significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.15

Identification of novel myeloma-specific XBP1 peptides able to generate cytotoxic T lymphocytes: a potential therapeutic application in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.15

Hedgehog signaling maintains a tumor stem cell compartment in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.15

Inhibition of Notch signaling induces apoptosis of myeloma cells and enhances sensitivity to chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.15

Targeting the beta-catenin/TCF transcriptional complex in the treatment of multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.15

Inhibition of the hedgehog pathway in advanced basal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.15

Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.15

Initial genome sequencing and analysis of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.15

FGFR3-targeted mAb therapy for bladder cancer and multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.15

Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.15

The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.15

The MMSET protein is a histone methyltransferase with characteristics of a transcriptional corepressor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.15

Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.15

Analysis of genetic abnormalities provides insights into genetic evolution of hyperdiploid myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.15

Oncogenomics to target myeloma in the bone marrow microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.15

Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.15

The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.15

Treatment of multiple myeloma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.15

Delineation of distinct subgroups of multiple myeloma and a model for clonal evolution based on interphase cytogenetics

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.15

Immunization with a recombinant MAGE-A3 protein after high-dose therapy for myeloma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.15

Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy.

31 March 2020

1 reference

12 December 2020

IPH-2101, a fully human anti-NK-cell inhibitory receptor mAb for the potential treatment of hematological cancers

1 reference

12 December 2020

Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in mice

1 reference

12 December 2020

Blockade of Hsp27 overcomes Bortezomib/proteasome inhibitor PS-341 resistance in lymphoma cells

1 reference

12 December 2020

10.1038/NRCLINONC.2012.15

Identifiers

DOI

1 reference

26 August 2017

1 reference